Lerakta

Lercanidipine Hydrochloride, the active ingredient in Lerakta, is a calcium channel blocker (dihydropyridine) presented as an oral tablet for systemic use. It is prescribed to lower elevated blood pressure in adult patients with hypertension by relaxing vascular smooth muscle and improving arterial compliance.

GNH USA supplies Lerakta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality through stringent manufacturing standards and regulatory compliance across EU and global markets.

Lerakta, a calcium channel blocker, is used in the management of hypertension.

Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications.

Lerakta may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache - Flushing - Peripheral edema - Dizziness

Serious or Rare Side Effects: - Severe hypotension - Myocardial infarction - Angioedema

When prescribing Lerakta, clinicians should consider several safety measures. - Monitor blood pressure regularly: adjust therapy based on response. - Use caution in hepatic impairment: reduced metabolism may increase exposure. - Avoid abrupt discontinuation: taper to prevent rebound hypertension. - Use with caution in elderly patients: increased sensitivity to hypotensive effects. - Contraindicated in severe hypotension: risk of further blood‑pressure drop. - Store at room temperature: keep in the original pack, protect from moisture.

Lerakta can interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise plasma concentrations. - Grapefruit juice: can increase drug levels and enhance hypotensive effect. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy.

Moderate Interactions (Monitor Closely): - Beta‑blockers: additive blood‑pressure lowering effect. - Diuretics: may enhance antihypertensive response. - NSAIDs: can blunt the blood‑pressure‑lowering effect of Lerakta.